de Smidt P C, van Berkel T J
Division of Biopharmaceutics, Center for Bio-Pharmaceutical Sciences, Sylvius Laboratory, University of Leiden, The Netherlands.
Pharm Res. 1992 Apr;9(4):565-9. doi: 10.1023/a:1015860901561.
In order to prepare cytotoxic drug-low density lipoprotein (LDL) particles, we have synthesized lipophilic prodrugs of two broad-spectrum antineoplastic agents, methotrexate (MTX) and 5-fluorodeoxyuridine (FUdR), by coupling them to oleic acid. 3H-Labeled prodrugs were incorporated in 125I-LDL carriers, allowing the study of both drug and carrier simultaneously. Utilizing the dry film procedure, monooleoyl FUdR showed the highest incorporation efficiency with over 40% of the initial drug associated with LDL. The prepared prodrug-LDL solution was found to be a single complex of 30 molecules of prodrug per LDL particle when examined by agarose gel electrophoresis and density gradient ultracentrifugation. No unbound FUdROl1 could be recovered, indicating that all dissolved prodrug associates with LDL. After incubation of FUdROl1 with human serum, 22% of the compound associates with lipoproteins and 78% was recovered in the albumin-containing fraction. When human serum was pretreated with oleic acid in order to saturate albumin's fatty acids binding sites, a strong decrease (from 78 to 22%) in association to the albumin-containing fraction was observed, accompanied by a threefold increase (from 22 to 67%) in lipoprotein association. It is concluded that existing hydrophilic antineoplastic agents can be successfully modified in order to achieve association with LDL. This may ultimately lead to an increased delivery of cytotoxic drugs to tumor cells.
为了制备细胞毒性药物 - 低密度脂蛋白(LDL)颗粒,我们通过将两种广谱抗肿瘤药物甲氨蝶呤(MTX)和5 - 氟脱氧尿苷(FUdR)与油酸偶联,合成了它们的亲脂性前药。将3H标记的前药掺入125I - LDL载体中,从而能够同时研究药物和载体。利用干膜法,单油酰基 - FUdR的掺入效率最高,超过40%的初始药物与LDL相关联。通过琼脂糖凝胶电泳和密度梯度超速离心法检测发现,所制备的前药 - LDL溶液是每个LDL颗粒含有30个前药分子的单一复合物。未检测到未结合的FUdROl1,这表明所有溶解的前药都与LDL结合。将FUdROl1与人血清孵育后,22%的化合物与脂蛋白结合,78%在含白蛋白的组分中回收。当用人血清与油酸预处理以饱和白蛋白的脂肪酸结合位点时,观察到与含白蛋白组分的结合显著减少(从78%降至22%),同时与脂蛋白的结合增加了三倍(从22%增至67%)。得出的结论是,现有的亲水性抗肿瘤药物可以成功修饰以实现与LDL结合。这最终可能导致细胞毒性药物向肿瘤细胞的递送增加。